Obagi Medical Unveils Clinical Data on New Anti-Aging Products at SCALE Meeting
Event summary
- Obagi Medical presented new data on NU-GEN Cellular Renewal Serum and Saypha® MagIQ™ filler at the SCALE meeting in Nashville (May 13-17, 2026).
- Interim results from the ALOHA program showed 94% of injectors believe MagIQ complements existing filler options.
- NU-GEN serum is clinically proven to reduce perceived skin age by up to six years in a 12-week study.
The big picture
Obagi Medical's data presentation underscores the growing emphasis on physician-dispensed skincare solutions with clinical backing. The ALOHA program represents an ambitious effort to gather real-world evidence, potentially setting a new standard for aesthetic product validation. Waldencast's ownership suggests strategic focus on scaling high-growth dermatology brands through operational synergies.
What we're watching
- Product Differentiation
- Whether Obagi can position MagIQ as a distinct offering in the competitive hyaluronic acid filler market.
- Clinical Validation
- The pace at which NU-GEN serum gains acceptance among dermatologists and plastic surgeons.
- Commercial Integration
- How Waldencast leverages Obagi's growth to strengthen its beauty platform portfolio.
Related topics